A detailed history of Jacobs Levy Equity Management, Inc transactions in Sangamo Therapeutics, Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 1,471,717 shares of SGMO stock, worth $3.64 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,471,717
Previous 2,950,944 50.13%
Holding current value
$3.64 Million
Previous $1.06 Million 19.11%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.32 - $1.1 $473,352 - $1.63 Million
-1,479,227 Reduced 50.13%
1,471,717 $1.27 Million
Q2 2024

Aug 14, 2024

BUY
$0.36 - $0.65 $993,238 - $1.79 Million
2,758,995 Added 1437.36%
2,950,944 $1.06 Million
Q1 2024

May 15, 2024

SELL
$0.42 - $1.38 $342,767 - $1.13 Million
-816,113 Reduced 80.96%
191,949 $128,000
Q4 2023

Feb 14, 2024

BUY
$0.3 - $0.63 $181,284 - $380,696
604,280 Added 149.66%
1,008,062 $544,000
Q3 2023

Nov 16, 2023

BUY
$0.58 - $1.47 $113,525 - $287,728
195,734 Added 94.08%
403,782 $242,000
Q2 2023

Aug 14, 2023

SELL
$1.11 - $1.74 $348,476 - $546,260
-313,943 Reduced 60.14%
208,048 $270,000
Q1 2023

May 15, 2023

BUY
$1.66 - $3.67 $671,415 - $1.48 Million
404,467 Added 344.16%
521,991 $918,000
Q4 2022

Feb 14, 2023

SELL
$2.77 - $5.07 $33,974 - $62,183
-12,265 Reduced 9.45%
117,524 $369,000
Q3 2022

Nov 15, 2022

BUY
$4.27 - $6.39 $131,426 - $196,677
30,779 Added 31.09%
129,789 $636,000
Q2 2022

Aug 15, 2022

BUY
$3.28 - $6.21 $324,752 - $614,852
99,010 New
99,010 $410,000
Q1 2018

May 15, 2018

SELL
$16.7 - $26.35 $677,018 - $1.07 Million
-40,540 Closed
0 $0
Q4 2017

Feb 13, 2018

BUY
$11.6 - $17.35 $106,720 - $159,620
9,200 Added 29.36%
40,540 $665,000
Q3 2017

Nov 14, 2017

BUY
$8.4 - $15.0 $263,256 - $470,100
31,340
31,340 $470,000

Others Institutions Holding SGMO

About SANGAMO THERAPEUTICS, INC


  • Ticker SGMO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 156,552,992
  • Market Cap $387M
  • Description
  • Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...
More about SGMO
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.